Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients: Systematic Review and Meta-Analysis
Pooled result · ATEResult — go to the resultRelative risk 0.73 95% CI 0.50–1.04Authors' conclusion
Anticoagulants did not reduce ATE risk among ambulatory patients on systemic anticancer therapy and were associated with increased bleeding.
Study context
- Population
- Ambulatory patients receiving systemic anticancer therapy with no other indication for anticoagulation14 RCTs
- Comparison
- Anticoagulation vs no anticoagulation
- Outcome
- ATE (MI, ischemic stroke, intra-abdominal arterial embolism or peripheral artery occlusion)
Pooled result
ATE
Relative risk
0.73
95% CI 0.50–1.04
P = 0.08
Anticoagulantsvs Placebo or standard treatment
RR 0.73 (95% CI 0.50–1.04); P = 0.08
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortality (13 trials)Anticoagulantsvs Placebo or standard treatmentI2 = 0% | 0.99 (0.95–1.02) | P = 0.38 | |
| 0.512Relative risk (log scale) |
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Major bleedingAnticoagulantsvs Placebo or standard treatment | 1.56 (1.12–2.17) | |
| Minor bleedingAnticoagulantsvs Placebo or standard treatment | 2.25 (1.45–3.48) | |
| 0.20.5125Relative risk (log scale) |
Original publication
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients: Systematic Review and Meta-Analysis. JACC CardioOncol. Published 27 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →